Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Feature|Articles|August 13, 2026
- Pharmaceutical Executive: August 2026
- Volume 46
- Issue 6
2026 Emerging Pharma Leaders
Author(s)Mike Hollan
Listen
0:00 / 0:00
From guiding pursuits in artificial intelligence and R&D to scientific marketing and company building, meet Pharm Exec’s new slate of select rising leaders who are helping to shape the next generation of biopharma innovation.
Advertisement
Follow the links below to read about each selection:
(In alphabetical order)
* These five selections were chosen from a pool of nominations evaluated by the Pharmaceutical Executive Editorial staff. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with those executives inhabiting key “C-suite” functions.
Articles in this issue
about 2 months ago
Pharmaceutical Executive: August 2026 Interactive Digital Editionabout 2 months ago
More Than Titles2 months ago
2026 Pharm Exec Top 50 Companies2 months ago
Making the Smart Career Moves2 months ago
Finding the Universal Truth in a Drug's Story2 months ago
What C-Suite Readiness Really RequiresAdvertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics on Sec61 inhibitor discovery.
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s full-year guidance.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
Advertisement
Advertisement
Trending on PharmExec
1
Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts
2
The Bottlenecks That Slow Manufacturer Response to Increased Demand for Production
3
Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeutics Enters Collaboration and License Agreement to Develop Sec61-Targeting Small Molecules
4
The Manufacturing Issues That Continue to Contribute to Drug Shortages
5